Biogen Inc.

Tweet this page
<
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
>
No longer registered as of 09 Mar 2023 - Registration as it was on 13 May 2022
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

500,000€ - 599,999€

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

2 Fte (4)

Lobbyists with EP accreditation

0

High-level Commission meetings

1

Lobbying Costs over the years

  • Info

    Biogen Inc.   (Biogen)

    EU Transparency Register

    966165310889-60 First registered on 26 Mar 2013

    Goals / Remit

    At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

    Main EU files targeted

    Biogen interacts with EU institutions and engages on issues relevant to Biogen and to the biopharmaceutical sector to develop a healthcare policy environment in which all patients have access to the medicines they need; pharmaceutical treatments are integrated into a continuum of care; financial returns attract investment; and the environment enables us to seek new innovative therapies and hopefully cures for this and future generations. We foster debates around the value of medical innovation including pharmaceutical incentives and rewards, sustainable healthcare systems, the future of neuroscience and patient access inequalities.

    In 2021, we monitored several policy and legislative initiatives including the implementation of the EU Pharmaceutical Strategy, debates and initiatives on pricing & access and sustainable health systems and on pharmaceutical incentives & rewards; the implementation of EU Regulations incl. data protection and clinical trials; the adoption of the European proposal on an EU Health Technology Assessment; the review of the OMP and Paediatric Regulations; EU rare disease policies, as well as policies and initiatives related to the use of medicines off-label, the prevention of and early intervention in non-communicable diseases with a focus on neurological diseases, demographic change and healthy ageing, Alzheimer's disease, competition in the pharmaceutical sector.

    Address

    Head Office
    225 Binney Street
    Cambridge MA 02142
    UNITED STATES
    EU Office
    Rue Belliard 40
    Bruxelles 1000
    BELGIUM

    Website

  • People

    Total lobbyists declared

    4

    Employment timeLobbyists
    75%1
    50%2
    25%1

    Lobbyists (Full time equivalent)

    2

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 29 Mar 2024

    Name Start date End Date
    Mr Alessandro Tempra 26 Nov 2021 26 Nov 2022
    Mr Andrea Corazza 28 Sep 2021 30 Jul 2022
    Mr Andrea Corazza 26 Feb 2020 26 Feb 2021
    Ms Andreea Antonovici 17 Jan 2020 01 Feb 2021
    Mr Alessandro Tempra 17 Jan 2020 01 Feb 2021
    Ms Isabel KLINNERT 20 Jul 2017 15 Jul 2018
    Emanuele DEGORTES 27 Jun 2017 19 Jun 2018
    Ms Tresja Bolt 23 Jan 2017 23 Jan 2018
    Mr Erwan Gicquel 03 Sep 2015 31 Aug 2016
    Ms Danuta Rydlewska 03 Sep 2015 31 Aug 2016
    Mr Erwan Gicquel 02 Aug 2014 31 Jul 2015
    Ms Danuta Rydlewska 02 Aug 2014 31 Jul 2015
    Mr Erwan Gicquel 07 Aug 2013 02 Aug 2014
    Ms Danuta Rydlewska 07 Aug 2013 02 Aug 2014

    Complementary Information

    Only 4 Biogen employees spent more than 10% of their respective work time in 2020 on this.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    In 2021 Biogen was a member of EFPIA, Eucope and the Alliance for Regenerative Medicines. We are also corporate partners of EU40 - The network of young MEPs and the Institute of Competitiveness (I-COM).

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    500,000€ - 599,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    incisive health 100,000€ - 199,999€
    edelman 0€ - 10,000€

    Intermediaries for current year

    Name
    edelman
    incisive health

    Closed year Costs

    500,000€ - 599,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    We have supported the organisation of a number of (virtual) events to raise awarness about key neurological diseases, from MS to Alzheimer's disease to rare neuromuscualr diseases, to which EU policy-makers were invited to speak and attend. To mark Rare Disease day we have launched a campaign entitled #Icare4rare that a number of Members of the European Parliament endorsed. We have also sponsored various articles in EU media outlets, such as Politico, the Parliament Magazine and Euractiv, to raise awarness about policy issues affecting key neurological diseases.

    Other activities

    None declared

  • Meetings

    Meetings

    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    • Date 27 Nov 2015 Location Brussels
      Subject Biopharmaceutical industry's contribution to jobs and growth
      Cabinet Cabinet of Vice-President Jyrki Katainen
      Portfolio Jobs, Growth, Investment and Competitiveness
      Attending
      • Grzegorz Radziejewski (Cabinet member)
      Other Lobbyists
Download this datacard